Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H I Miller

Showing results (11-20 of 186) with videos related to

Pageof 19
Sort By:
JAMA|September 24, 1982
Designer genes for producing drugs: will they wash?H I Miller
Nature Biotechnology|February 1, 1997
The end of big government?H I Miller
Human Gene Therapy|April 1, 1993
"Single patient use" and "emergency use" situations in drug review by the Food & Drug AdministrationH I Miller
Human Gene Therapy|November 1, 1995
Overregulation is an unnecessary hindrance to human gene therapyH I Miller
Trends in Biotechnology|August 1, 1994
Risk-assessment experiments and the new biotechnologyH I Miller
Nature|June 30, 1994
Wrong committees axed?H I Miller
Nature Biotechnology|July 1, 1996
Biotechnology and the UN: new challenges, new failuresH I Miller
Journal of Parenteral Science and Technology : a Publication of the Parenteral Drug Association|November 1, 1982
Recombinant DNA as a paradigm of a new technology: its impact on regulation by the Food and Drug AdministrationH I Miller
Science (New York, N.Y.)|February 26, 2000
Gene therapy on trialH I Miller
Nature|November 6, 1998
Rising costs hold up drug discoveryH I Miller
Pageof 19

Showing results (11-20 of 186) with videos related to

Sort By:
Pageof 19
JAMA|September 24, 1982
Designer genes for producing drugs: will they wash?H I Miller
Nature Biotechnology|February 1, 1997
The end of big government?H I Miller
Human Gene Therapy|April 1, 1993
"Single patient use" and "emergency use" situations in drug review by the Food & Drug AdministrationH I Miller
Human Gene Therapy|November 1, 1995
Overregulation is an unnecessary hindrance to human gene therapyH I Miller
Trends in Biotechnology|August 1, 1994
Risk-assessment experiments and the new biotechnologyH I Miller
Nature|June 30, 1994
Wrong committees axed?H I Miller
Nature Biotechnology|July 1, 1996
Biotechnology and the UN: new challenges, new failuresH I Miller
Journal of Parenteral Science and Technology : a Publication of the Parenteral Drug Association|November 1, 1982
Recombinant DNA as a paradigm of a new technology: its impact on regulation by the Food and Drug AdministrationH I Miller
Science (New York, N.Y.)|February 26, 2000
Gene therapy on trialH I Miller
Nature|November 6, 1998
Rising costs hold up drug discoveryH I Miller
Pageof 19